Ajooni Biotech Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ajooni Biotech Limited's yearly results (2023–2026), compared with Consumer Defensive companies in India. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 73% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 97% of Consumer Defensive companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹-150 of operating cash. Lower than 97% of Consumer Defensive companies in India.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 92% of Consumer Defensive companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹-150Over the last 3 years, every ₹100 of reported profit came with ₹-150 of operating cash.
Lower than 97% of Consumer Defensive companies in India.
Self-Funding Ratio
-0.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 91% of Consumer Defensive companies in India.
Cash Locked Ratio
₹26For every ₹100 of sales, ₹26 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹23 tied up three years earlier.
More money tied up than 63% of Consumer Defensive companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 90% of Consumer Defensive companies in India.
Growth Efficiency Ratio
₹3Sales grew 145% in 3 years; of every extra ₹100 of sales, ₹3 became extra profit.
Lower than 67% of Consumer Defensive companies in India.
Asset Productivity Ratio
+145% / +105%In 3 years sales changed by +145% while total assets changed by +105%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-0.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 92% of Consumer Defensive companies in India.
Cash Cushion Ratio
−33%Debt, after subtracting cash, equals 33% of its market value (net debt).
Lower than 73% of Consumer Defensive companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 52% of Consumer Defensive companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 52% of Consumer Defensive companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Ajooni Biotech Limited owes ₹0.24 for every ₹1 it owns. Net profit rose 28% in the year to Mar 2026, and grew 57% a year on average over 3 years.
Compared with Consumer Defensive companies in India · latest annual results Mar 2026.
P/E ratio
11.8Investors pay ₹11.8 for every ₹1 of Ajooni Biotech Limited's yearly profit, lower than 78% of Consumer Defensive companies in India.
P/B ratio
0.56The share price is 0.56 times Ajooni Biotech Limited's book value per share, lower than 90% of Consumer Defensive companies in India.
Market cap
₹51 CrThe total market value of all of Ajooni Biotech Limited's shares at today's price (share price × number of shares), smaller than 94% of Consumer Defensive companies in India. PosiCap size class: Nano Cap.
Net worth (book value)
₹91 CrWhat Ajooni Biotech Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹5.29Net worth divided by the number of shares. The share price of ₹2.94 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
4.4%Ajooni Biotech Limited earned 4.4% on its shareholders' money over the last year, lower than 78% of Consumer Defensive companies in India.
Owes vs Owns
0.24×Ajooni Biotech Limited owes ₹0.24 for every ₹1 it owns (low), lower than 75% of Consumer Defensive companies in India.
Dividend yield
NoneAjooni Biotech Limited does not currently pay a dividend.
Revenue growth
+59%Revenue rose 59% in the year to Mar 2026, and grew 35% a year on average over 3 years.
Profit growth
+28%Net profit rose 28% in the year to Mar 2026, and grew 57% a year on average over 3 years.
Profit margin
2.4%Ajooni Biotech Limited keeps ₹2 of every ₹100 of revenue as net profit.
Cash quality
-1.3×Cash from Ajooni Biotech Limited's business was -1.3× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
5.9×Ajooni Biotech Limited's operating profit covered its interest costs 5.9 times in the year to Mar 2026.
Cash vs debt
Net debtAjooni Biotech Limited had ₹17 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Ajooni Biotech Limited's P/E ratio?
Investors pay ₹11.8 for every ₹1 of Ajooni Biotech Limited's yearly profit, lower than 78% of Consumer Defensive companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Ajooni Biotech Limited: ₹51 Cr ÷ ₹91 Cr (31 Mar 2026) = 0.6.
What is Ajooni Biotech Limited's return on equity?
Ajooni Biotech Limited earned 4.4% on its shareholders' money over the last year, lower than 78% of Consumer Defensive companies in India.
How much does Ajooni Biotech Limited owe compared with what it owns?
Ajooni Biotech Limited owes ₹0.24 for every ₹1 it owns (low), lower than 75% of Consumer Defensive companies in India.
Does Ajooni Biotech Limited pay a dividend?
No. Ajooni Biotech Limited does not currently pay a dividend.
Is Ajooni Biotech Limited's revenue growing?
Revenue rose 59% in the year to Mar 2026, and grew 35% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.